InvestorsHub Logo
Followers 65
Posts 23985
Boards Moderated 0
Alias Born 11/23/2016

Re: Investor2014 post# 120697

Tuesday, 09/19/2017 5:09:27 AM

Tuesday, September 19, 2017 5:09:27 AM

Post# of 463990
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504819/

If I understand this right, the HDAC inhibitor approach is not upstream of the actual cellular problems and decease modifying, like A2-73 Sig-1/Muscarin approach, and has side effect issues.

So maybe, just maybe, that is related to Biogen's shifting priorities...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News